Perindopril safety and tolerance in at-risk patients
Related Experiment Video
Updated: Oct 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
1Department of Internal Medicine, University of Louvain School of Medicine, Brussels, Belgium.
Abstract:
The angiotensin-converting enzyme (ACE) inhibitors are effective in the treatment of hypertension and congestive heart failure. They improve the quality of life when compared with other conventional antihypertensive drugs. Perindopril, a new ACE inhibitor, is well tolerated and associated with fewer side effects than other types of antihypertensive agents. Moreover, it does not induce adverse metabolic changes such as hyperglycaemia and/or alterations in the blood lipid profile that could negate the benefits of lowering blood pressure. In hypertensive diabetic patients, perindopril decreases microalbuminuria without affecting the quality of glycaemic control and thereby may delay the progression of nephropathy. Therefore, perindopril appears to be an alternative first-line antihypertensive agent which may be useful in hypertensive diabetics.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Dosing: Geriatric Patients
Drug Toxicity: Risk factors
Acute Kidney Injury IV: Diagnostic Studies and Prevention